Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
203 hedge funds and large institutions have $1.29B invested in Meridian Bioscience Inc in 2022 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 61 closing their positions.
75% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $2.12M
4% less capital invested
Capital invested by funds: $1.35B → $1.29B (-$57.8M)
9% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 65
6% less funds holding
Funds holding: 216 → 203 (-13)
20% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 61
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$72.8M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$33.9M |
| 3 |
Goldman Sachs
New York
|
+$24.1M |
| 4 |
Millennium Management
New York
|
+$23.7M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
-$115M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.1M |
| 3 |
RA
Royce & Associates
New York
|
-$48.8M |
| 4 |
IC
Impactive Capital
New York City,
New York
|
-$46.5M |
| 5 |
VLKIM
Van Lanschot Kempen Investment Management
Amsterdam,
Netherlands
|
-$40.6M |
VIVO Hedge Fund Activity: Q3 2022 in Review
203 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q3 2022, worth a combined $1.29B — down 4.3% from $1.35B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of VIVO and 49 opened new positions — a net loss of 12 holders — while 65 trimmed existing stakes and 59 added.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $72.8M. The largest seller was EARNEST Partners, cutting an estimated $115M.
- 203 institutional investors held Meridian Bioscience Inc (VIVO) as of Q3 2022, down from 216 in Q2 2022.
- Funds reported $1.29B of Meridian Bioscience Inc stock for Q3 2022, down 4.3% quarter-over-quarter.
- 49 funds opened new Meridian Bioscience Inc positions in Q3 2022 and 61 closed out, a net change of -12 holders.
- The largest Meridian Bioscience Inc buyer in Q3 2022 was Magnetar Financial, an estimated $72.8M added.
- The largest Meridian Bioscience Inc seller in Q3 2022 was EARNEST Partners, an estimated $115M sold.
Based on aggregated 13F filings for Q3 2022.